About Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial
Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial (DUT) is a protein
from Homo sapiens identified by UniProt accession
P33316, 252 residues long.
MolForge cross-references it against 0 known binders and
112 disease associations.
Target properties
| Protein name | Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial |
|---|
| UniProt accession | P33316 |
|---|
| Gene | DUT |
|---|
| Organism | Homo sapiens |
|---|
| Length | 252 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (112)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.55
- lymphocyte count · score 0.41
- blood protein measurement · score 0.25
- neutrophil percentage of leukocytes · score 0.23
- body height · score 0.20
- lymphocyte percentage of leukocytes · score 0.20
- BMI-adjusted waist circumference · score 0.17
- lean body mass · score 0.16
- fat body mass · score 0.15
- sitting height measurement · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P33316-F1 | alphafold | PREDICTED | 74.30 | — |
Amino-acid sequence (252 residues)
MTPLCPRPAL CYHFLTSLLR SAMQNARGAR QRAEAAVLSG PGPPLGRAAQ HGIPRPLSSA GRLSQGCRGA STVGAAGWKG ELPKAGGSPA PGPETPAISP SKRARPAEVG GMQLRFARLS EHATAPTRGS ARAAGYDLYS AYDYTIPPME KAVVKTDIQI ALPSGCYGRV APRSGLAAKH FIDVGAGVID EDYRGNVGVV LFNFGKEKFE VKKGDRIAQL ICERIFYPEI EEVQALDDTE RGSGGFGSTG KN
Explore Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets